Obesity and Weight Loss Strategies for Patients With Heart Failure

被引：9

作者：

Vest, Amanda R. ^{[1
]}

Schauer, Philip R. ^{[2
]}

Rodgers, Jo E. ^{[3
]}

Sanderson, Emily ^{[4
]}

LaChute, Courtney L. ^{[5
]}

Seltz, Jessica ^{[6
]}

Lavie, Carl J. ^{[7
,8
]}

Mandras, Stacy A. ^{[9
]}

Tang, W. H. Wilson ^{[10
]}

daSilva-deAbreu, Adrian ^{[10
,11
]}

机构：

[1] Cleveland Clin, Heart Vasc & Thorac Inst, Kaufman Ctr Heart Failure Treatment & Recovery, Dept Cardiovasc Med, Cleveland, OH USA

[2] Metamor Metab Inst, Pennington Biomed Res Ctr, Baton Rouge, LA USA

[3] Univ North Carolina, UNC Eshelman Sch Pharm, Div Pharmacotherapy & Expt Therapeut, Chapel Hill, NC USA

[4] Tufts Univ, Friedman Sch Nutr Sci & Policy, Boston, MA USA

[5] Louisiana State Univ, Dept Med, Baton Rouge, LA USA

[6] Tufts Med Ctr, Frances Stern Nutr Ctr, Boston, MA USA

[7] Ochsner Med Ctr, Dept Cardiol, New Orleans, LA USA

[8] Univ Queensland, Ochsner Clin Sch, New Orleans, LA USA

[9] AdventHlth Orlando, Transplant Inst, Orlando, FL USA

[10] Univ Las Palmas Gran Canaria, Doctoral Sch, Las Palmas Gran Canaria, Spain

[11] Mayo Clin, Dept Cardiovasc Med, Rochester, MN USA

来源：

JACC-HEART FAILURE | 2024年 / 12卷 / 09期

关键词：

bariatric surgery; heart failure; lifestyle; metabolism; nutrition; obesity; physical activity; weight loss; BODY-MASS INDEX; NATRIURETIC PEPTIDE LEVELS; REDUCED EJECTION FRACTION; LEFT-VENTRICULAR FUNCTION; BARIATRIC SURGERY; CARDIOVASCULAR OUTCOMES; DOUBLE-BLIND; EXERCISE CAPACITY; PHYSICAL-ACTIVITY; FUNCTIONAL STATUS;

D O I：

10.1016/j.jchf.2024.06.006

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Obesity is a common comorbidity among patients with heart failure with reduced ejection fraction (HFrEF) or heart failure with preserved ejection fraction (HFpEF), with the strongest pathophysiologic link of obesity being seen for HFpEF. Lifestyle measures are the cornerstone of weight loss management, but sustainability is a challenge, and there are limited efficacy data in the heart failure (HF) population. Bariatric surgery has moderate efficacy and safety data for patients with preoperative HF or left ventricular dysfunction and has been associated with reductions in HF hospitalizations and medium-term mortality. Antiobesity medications historically carried concerns for cardiovascular adverse effects, but the safety and weight loss efficacy seen in general population trials of glucagon-like peptide 1 (GLP-1) and gastric inhibitory polypeptide/GLP-1 agonists are highly encouraging. Although there are safety concerns regarding GLP-1 agonists in advanced HFrEF, trials of the GLP-1 agonist semaglutide for treatment of obesity have confirmed safety and efficacy in patients with HFpEF. (c) 2024 by the American College of Cardiology Foundation.

引用

页码：1509 / 1527

页数：19

共 153 条

[1] Dapagliflozin for heart failure according to body mass index: the DELIVER trial [J].

Adamson, Carly ;

Kondo, Toru ;

Jhund, Pardeep ;

de Boer, Rudolf A. ;

Honorio, Jose Walter Cabrera ;

Claggett, Brian ;

Desai, Akshay S. ;

Gamba, Marco Antonio Alcocer ;

Al Habeeb, Waleed ;

Hernandez, Adrian F. ;

Inzucchi, Silvio E. ;

Kosiborod, Mikhail N. ;

Lam, Carolyn S. P. ;

Langkilde, Anna Maria ;

Lindholm, Daniel ;

Bachus, Erasmus ;

Litwin, Sheldon E. ;

Martinez, Felipe ;

Petersson, Magnus ;

Shah, Sanjiv J. ;

Vaduganathan, Muthiah ;

Vinh, Pham Nguyen ;

Wilderang, Ulrica ;

Solomon, Scott D. ;

McMurray, John Jv .

EUROPEAN HEART JOURNAL, 2022, 43 (41) :4406-4417

[2] Impact of bariatric surgery on heart failure mortality [J].

Aleassa, Essa M. ;

Khorgami, Zhamak ;

Kindel, Tammy L. ;

Tu, Chao ;

Tang, W. H. Wilson ;

Schauer, Philip R. ;

Brethauer, Stacy A. ;

Aminian, Ali .

SURGERY FOR OBESITY AND RELATED DISEASES, 2019, 15 (07) :1189-1196

[3] Wasting as independent risk factor for mortality in chronic heart failure [J].

Anker, SD ;

Ponikowski, P ;

Varney, S ;

Chua, TP ;

Clark, AL ;

WebbPeploe, KM ;

Harrington, D ;

Kox, WJ ;

PooleWilson, PA ;

Coats, AJS .

LANCET, 1997, 349 (9058) :1050-1053

[4]

[Anonymous], 2018, Liraglutide package insert

[5]

[Anonymous], 2021, Semaglutide package insert

[6]

[Anonymous], 2022, Indianapolis

[7] Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline [J].

Apovian, Caroline M ;

Aronne, Louis J. ;

Bessesen, Daniel H. ;

McDonnell, Marie E. ;

Murad, M. Hassan ;

Pagotto, Uberto ;

Ryan, Donna H. ;

Still, Christopher D. .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2015, 100 (02) :342-362

[8] 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines (vol 74, pg 1376, 2019) [J].

Arnett, D. K. ;

Blumenthal, R. S. ;

Albert, M. A. ;

Buroker, A. B. ;

Goldberger, Z. D. ;

Hahn, E. J. ;

Himmelfarb, C. D. ;

Khera, A. ;

Lloyd-Jones, D. ;

McEvoy, J. W. ;

Michos, E. D. ;

Miedema, M. D. ;

Munoz, D. ;

Smith, S. C., Jr. ;

Virani, S. S. ;

Williams, K. A., Jr. ;

Yeboah, J. ;

Ziaeian, B. .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2019, 74 (10) :1428-1429

[9] Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials [J].

Aroda, V. R. ;

Ahmann, A. ;

Cariou, B. ;

Chow, F. ;

Davies, M. J. ;

Jodar, E. ;

Mehta, R. ;

Woo, V ;

Lingvay, I .

DIABETES & METABOLISM, 2019, 45 (05) :409-418

[10] Benefits and Risks of Bariatric Surgery in Adults A Review [J].

Arterburn, David E. ;

Telem, Dana A. ;

Kushner, Robert F. ;

Courcoulas, Anita P. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2020, 324 (09) :879-887

← 1 2 3 4 5 6 7 8 9 10 →